Clinical trial
Fondaparinux to Prevent Thrombotic Complications and Graft Failure in Patients…
NCT00474591 · Hamilton Health Sciences Corporation, Other · Unknown status
Key facts
| NCT number | NCT00474591 |
|---|---|
| Title | Fondaparinux to Prevent Thrombotic Complications and Graft Failure in Patients Undergoing Coronary Artery Bypass Graft Surgery: The Fonda CABG Study |
| Official title | Fondaparinux Compared With Heparin to Prevent Thrombotic Complications and Graft Failure in Patients Undergoing Coronary Artery Bypass Graft Surgery |
| Acronym | Fonda CABG |
| Lead sponsor | Hamilton Health Sciences Corporation, Other |
| Collaborators | GlaxoSmithKline Industry |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Coronary Bypass Graft Failure/Occlusion |
| Intervention type | Drug |
| Interventions | Fondaparinux |
| Enrollment | 100 |
| First posted | May 17, 2007 |
| Last update posted | May 28, 2007 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: